Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ARCT Arcturus Therapeutics Ltd.

Market Closed 02-14 16:00:00 EST

18.05

+1.64

+9.99%

盘后18.00

-0.05-0.28%

19:54 EST

High18.89	Low16.50	Vol843.04K
Open16.50	D1 Closing16.41	Amplitude14.53%
Mkt Cap488.93M	Tradable Cap447.66M	Total Shares27.09M
T/O14.96M	T/O Rate3.40%	Tradable Shares24.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ARCT","market":"US","secType":"STK","nameCN":"Arcturus Therapeutics Ltd.","latestPrice":18.05,"timestamp":1739566800000,"preClose":16.41,"halted":0,"volume":843040,"hourTrading":{"tag":"盘后","latestPrice":18,"preClose":18.05,"latestTime":"19:54 EST","volume":87025,"amount":1570967.77,"timestamp":1739580865526},"delay":0,"floatShares":24801158,"shares":27087359,"eps":-2.329253,"marketStatus":"Market Closed","change":1.64,"latestTime":"02-14 16:00:00 EST","open":16.5,"high":18.885,"low":16.5,"amount":14962518.401600001,"amplitude":0.145338,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.329253,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1739869200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":16.41,"preHourTrading":{"tag":"盘前","latestPrice":16.5,"preClose":16.41,"latestTime":"09:28 EST","volume":9711,"amount":161874.42640199998,"timestamp":1739543330900},"postHourTrading":{"tag":"盘后","latestPrice":18,"preClose":18.05,"latestTime":"19:54 EST","volume":87025,"amount":1570967.77,"timestamp":1739580865526},"volumeRatio":2.2273016433082726,"impliedVol":0.7108,"impliedVolPercentile":0.3307},"requestUrl":"/m/hq/s/ARCT","defaultTab":"news","newsList":[{"id":"2511158346","title":"Arcturus Therapeutics Price Target Maintained With a $63.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2511158346","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511158346?lang=en_us&edition=fundamental","pubTime":"2025-02-15 02:03","pubTimestamp":1739556180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARCT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 14, 2025 13:03 ET (18:03 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCT","LENZ"],"gpt_icon":0},{"id":"2511807693","title":"Arcturus Therapeutics Says EU Commission Approves COVID-19 Vaccine Kostaive","url":"https://stock-news.laohu8.com/highlight/detail?id=2511807693","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511807693?lang=en_us&edition=fundamental","pubTime":"2025-02-14 21:47","pubTimestamp":1739540878,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics  said Friday the European Commission granted marketing authorization for Kostaive, a self-amplifying mRNA COVID-19 vaccine for individuals aged 18 and above.The biotechnology company said Kostaive is the first self-amplifying mRNA COVID vaccine to receive European Commission clearance and is currently marketed in Japan against the disease.Kostaive showed \"superior\" immunogenicity and maintained antibody levels for up to 12 months post-vaccination compared to traditional mRNA vaccines, the company said.The company also said that the approval follows a favorable opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency on Dec. 12 and is valid across all European countries.The company's shares were up 2.1% in recent premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4156","LENZ","BK4139","ARCT","BNTX"],"gpt_icon":1},{"id":"2511660068","title":"European Commission Approves CSL and Arcturus Therapeutics' Kostaive®, the First Self-Amplifying Mrna Covid-19 Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2511660068","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511660068?lang=en_us&edition=fundamental","pubTime":"2025-02-14 21:30","pubTimestamp":1739539804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nTUA2RQQ7G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARCT","BK7067","BK4139","BK7501","BK7508","CSL.AU","BK7511"],"gpt_icon":0},{"id":"2511667960","title":"European Commission Approves CSL and Arcturus Therapeutics’ Kostaive®, the First Self-Amplifying Mrna Covid-19 Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2511667960","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511667960?lang=en_us&edition=fundamental","pubTime":"2025-02-14 21:00","pubTimestamp":1739538001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nTUA9KMGMP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7067","BK4139","BK7501","BK7511","ARCT","BK7508"],"gpt_icon":0},{"id":"2510809100","title":"Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains?","url":"https://stock-news.laohu8.com/highlight/detail?id=2510809100","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510809100?lang=en_us&edition=fundamental","pubTime":"2025-02-11 16:33","pubTimestamp":1739262780,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics  shares soared 20.2% in the last trading session to close at $127.08. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 32.1% gain over the past four weeks.This biopharmaceutical company is expected to post quarterly loss of $0.97 per share in its upcoming report, which represents a year-over-year change of -32.9%. Revenues are expected to be $117.84 million, up 64.7% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.For Axsome, the consensus EPS estimate for the quarter has been revised 1.6% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on AXSM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/axsome-axsm-surges-20-2-083300861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","ARCT","BK4505","BK4007","BK4139","AXSM"],"gpt_icon":0},{"id":"2508463290","title":"Arcturus Therapeutics Appoints Moncef Slaoui Chair Designate","url":"https://stock-news.laohu8.com/highlight/detail?id=2508463290","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508463290?lang=en_us&edition=fundamental","pubTime":"2025-02-04 23:39","pubTimestamp":1738683583,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings  said Tuesday it has appointed Moncef Slaoui as chair designate.Slaoui has been a member of the company's board since June 2024 and most recently served as chief scientific advisor to the White House's Operation Warp Speed, according to Arcturus.Price: 15.73, Change: -0.07, Percent Change: -0.44","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARCT","BK4139","LENZ","MRNA"],"gpt_icon":0},{"id":"2508549934","title":"Arcturus Therapeutics appoints Moncef Slaoui as chair designate","url":"https://stock-news.laohu8.com/highlight/detail?id=2508549934","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508549934?lang=en_us&edition=fundamental","pubTime":"2025-02-04 21:55","pubTimestamp":1738677326,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics (ARCT) announced the appointment of Moncef Slaoui as chair designate. Slaoui has been serving on the company’s board of direc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arcturus-therapeutics-appoints-moncef-slaoui-as-chair-designate?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arcturus-therapeutics-appoints-moncef-slaoui-as-chair-designate?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","BK4548","ARCT","BK4533","MRNA","LENZ","BK4139","BK4534","BK4568","BK4551","BK4585","BK4501","BK4588"],"gpt_icon":0},{"id":"2508459941","title":"Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.d., as Chair Designate","url":"https://stock-news.laohu8.com/highlight/detail?id=2508459941","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508459941?lang=en_us&edition=fundamental","pubTime":"2025-02-04 21:30","pubTimestamp":1738675803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250204:nTUABGHDT8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARCT","BK4139"],"gpt_icon":0},{"id":"2508895451","title":"Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate","url":"https://stock-news.laohu8.com/highlight/detail?id=2508895451","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508895451?lang=en_us&edition=fundamental","pubTime":"2025-02-04 21:30","pubTimestamp":1738675800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, February 04, 2025----Arcturus Therapeutics Holdings Inc. , a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the appointment of Moncef Slaoui, Ph.D., as Chair Designate. Dr. Slaoui has been serving on the Company’s Board of Directors since June 2024.\"Arcturus has deep expertise in mRNA delivery for therapeutics and a validated commercial stage vaccines platform,\" said Dr. Moncef Slaoui. \"I am excited to work with the company during this potentially transformational time with multiple key data readouts across its pipeline.\". Dr. Slaoui holds a Ph.D. in Molecular Biology and Immunology from the Université Libre de Bruxelles, completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, and was a Professor of Immunology at the University of Mons, Belgium. He received an accelerated Master of Business Administratio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-announces-appointment-moncef-133000305.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MRNA","RNA","BK4588","BK4585","BK4093","BK4139","LU1829250122.USD","BK4568","BK4501","ARCT","BK4007","BK4551","GSK.UK","BK4533","BK4532","GSK","CF","LENZ","BK4505","BK4548","BK4534"],"gpt_icon":1},{"id":"2507934634","title":"Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for Kostaive®, a Self-Amplifying Mrna Vaccine Against Covid-19","url":"https://stock-news.laohu8.com/highlight/detail?id=2507934634","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507934634?lang=en_us&edition=fundamental","pubTime":"2025-01-31 16:00","pubTimestamp":1738310400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250131:nTUA57HBSC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARCT"],"gpt_icon":0},{"id":"2507934643","title":"Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=2507934643","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507934643?lang=en_us&edition=fundamental","pubTime":"2025-01-31 16:00","pubTimestamp":1738310400,"startTime":"0","endTime":"0","summary":"TOKYO, January 31, 2025----Meiji Seika Pharma Co., Ltd.  announced today that it has received approval for a partial amendment to the manufacturing and marketing approval of \"KOSTAIVE for Intramuscular Injection,\" a self-amplifying mRNA vaccine for protection against COVID-19, to include domestic manufacturing sites in Japan.Meiji Seika Pharma and ARCALIS Co., Ltd.  have been working together to establish an infrastructure that enables the integrated production of pharmaceuticals, from active ingredients to final products, within Japan. With this approval, ARCALIS’s Minami-soma facilities and Meiji Seika Pharmatech Co., Ltd., a subsidiary of Meiji Seika Pharma, have been added as manufacturing sites. The technology transfer was managed and implemented by CSL Seqirus, the global licensor of KOSTAIVE. As a result, domestically produced products, with active pharmaceutical ingredients manufactured at ARCALIS's Minami-soma facilities and formulated at Meiji Seika Pharmatech, are now able t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/meiji-seika-pharma-receives-approval-080000736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4551","BK4548","BK4568","BK4585","BK4588","BNTX","ARCT","BK4535","BK4139"],"gpt_icon":0},{"id":"2507605449","title":"Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507605449","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507605449?lang=en_us&edition=fundamental","pubTime":"2025-01-31 05:01","pubTimestamp":1738270860,"startTime":"0","endTime":"0","summary":"SAN DIEGO, January 30, 2025----Arcturus Therapeutics Holdings Inc. , a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate at a fireside chat hosted by Guggenheim Securities SMID Cap Biotech Conference in New York, on Thursday, February 6, 2025, at 10:30 a.m. Eastern Time.Webcast link can be found under Investor Relations/Events section of Arcturus’ website.Arcturus Therapeutics Public Relations & Investor RelationsNeda SafarzadehVP, Head of IR/PR/Marketing 900-2682IR@ArcturusRx.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-present-guggenheim-securities-210100312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4011","BK4585","RNA","ARCT","BK4505","SMID","CF","BK4093","BK4139","BK4588","LENZ"],"gpt_icon":0},{"id":"2506188597","title":"BTIG Initiates Arcturus Therapeutics Holdings at Buy With $41 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2506188597","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506188597?lang=en_us&edition=fundamental","pubTime":"2025-01-28 20:08","pubTimestamp":1738066110,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings (ARCT) has an average rating of buy and mean price target of $75.62, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","ARCT"],"gpt_icon":0},{"id":"2506591300","title":"Arcturus Therapeutics initiated with a Buy at BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2506591300","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506591300?lang=en_us&edition=fundamental","pubTime":"2025-01-28 18:40","pubTimestamp":1738060809,"startTime":"0","endTime":"0","summary":"BTIG initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $41 price target Arcturus is a commercial-stage biotechnology company...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arcturus-therapeutics-initiated-with-a-buy-at-btig?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arcturus-therapeutics-initiated-with-a-buy-at-btig?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARCT","BK4139","LENZ"],"gpt_icon":0},{"id":"2504129161","title":"Moderna Is Getting $590 Million From the U.S. to Accelerate a Bird Flu Vaccine -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2504129161","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504129161?lang=en_us&edition=fundamental","pubTime":"2025-01-18 05:42","pubTimestamp":1737150120,"startTime":"0","endTime":"0","summary":"The federal government has committed an additional $590 million to push Moderna's messenger RNA-based pandemic flu vaccine towards approval, as the Biden administration, in its waning hours, ramps up preparations for a potential H5N1 avian influenza pandemic.The award is a large sum for the U.S. Department of Health and Human Services division known as BARDA, which last year gave Moderna $176 million to fund development of the shot, and which rarely announces contracts worth more than $150 million.Shares of Moderna were up 4% in after-hours trading Friday.The government's recent funding for Moderna's mRNA bird flu shot now totals $766 million, approaching the $995 million spent on the company's Covid-19 shot in early 2020. It's a sign of the seriousness with which HHS appears to be taking the pandemic threat.Moderna sales have plummeted since 2022, as the Covid-19 vaccine market dried up, and the company has announced significant cost cuts, as it tries to preserve its cash hoard and av","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"695ee1f9e6bbf493b88c462b72b41800","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4568","BK4588","BK4551","BK4139","GSK","IE00BFXG1179.USD","GSK.UK","PFE","MRNA","BK4007","BK4501","BK4534","ARCT","BK4533","LU1829250122.USD","BK4585","AAQC","SNY","BK4532"],"gpt_icon":1},{"id":"2503534581","title":"Moderna's Struggles Could Complicate Bird Flu Fight. What It Means for a Potential Vaccine. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2503534581","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503534581?lang=en_us&edition=fundamental","pubTime":"2025-01-14 02:59","pubTimestamp":1736794740,"startTime":"0","endTime":"0","summary":"After Moderna proved in 2021 that messenger RNA vaccines could blunt the impact of a pandemic, it seemed the playbook for future outbreaks was set: A few months of vaccine trials, and then an avalanche of doses that would blanket the globe.Moderna alone sold 800 million doses of its Covid-19 vaccine in 2021. That recent history has served as a sort of balm in recent months, as the bird flu known as H5N1 has swept through dairy farms and poultry flocks across the U.S., and infected a small but growing number of humans.But since its Covid-19 success, Moderna has cut costs in the face of weaker demand, falling revenue, and sagging stock. On Monday, shares tumbled 20% after the company's latest vaccine forecast sparked concerns about the company's financial staying power.In a press release laying out its financial update Monday, Moderna didn't say anything about the status of its mRNA-based bird flu vaccine, which the U.S. Department of Health and Human Services gave the company $176 milli","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4501","BK4548","BK4585","BK4534","BK4588","BK4533","ARCT","BK4568","BK4551","MRNA","BK4139","BK4532"],"gpt_icon":1},{"id":"2502137865","title":"BRIEF-Arcturus Therapeutics Initiates Phase 1 H5N1 Flu Vaccine Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2502137865","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502137865?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:29","pubTimestamp":1736515785,"startTime":"0","endTime":"0","summary":"Jan 10 (Reuters) - Arcturus Therapeutics Holdings Inc :   * ARCTURUS THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 H5N1 FLU VACCINE TRIAL   * ARCTURUS THERAPEUTICS HOLDINGS INC - INTERIM PHASE 1 DATA EXPECTED H2 2025Source text:   Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCT","BK4139","LENZ"],"gpt_icon":0},{"id":"2502868424","title":"Arcturus Therapeutics Holdings Inc - Interim Phase 1 Data Expected H2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2502868424","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502868424?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:00","pubTimestamp":1736514004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUA3Z5PJH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARCT","BK4139"],"gpt_icon":0},{"id":"2502681688","title":"Arcturus Therapeutics Announces Initiation of Phase 1 H5n1 Flu Vaccine Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2502681688","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502681688?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:00","pubTimestamp":1736514004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUA3Z5PJH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARCT","BK4139"],"gpt_icon":0},{"id":"2502186536","title":"Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2502186536","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502186536?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:00","pubTimestamp":1736514000,"startTime":"0","endTime":"0","summary":"LUNAR-H5N1 becomes the third STARR mRNA vaccine candidate to enter clinic. SAN DIEGO, January 10, 2025----Arcturus Therapeutics Holdings Inc. , a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the initiation of the Company’s Phase 1 study of ARCT-2304, a self-amplifying mRNA  vaccine candidate, also known as LUNAR-H5N1, for active immunization to prevent pandemic influenza disease caused by H5N1 virus.ARCT-2304  utilizes clinically validated LUNAR delivery and STARR mRNA platform technologies. STARR mRNA has demonstrated in multiple clinical trials its ability to elicit a robust immune response at very low dose levels, with extended persistence of neutralizing antibodies compared to approved conventional mRNA vaccines. The robust safety database of the LUNAR and STARR technologies have been established through multiple COVID-19 and seasonal influenza vacci","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-announces-initiation-phase-130000469.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4008","NA","BK4139","ARCT","BK4141","HA","BK4093","LENZ","CF","RNA","BK4585","BK4505","BK4500","BK4588"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arcturusrx.com","stockEarnings":[{"period":"1week","weight":0.1149},{"period":"1month","weight":0.077},{"period":"3month","weight":0.1267},{"period":"6month","weight":-0.1064},{"period":"1year","weight":-0.5274},{"period":"ytd","weight":0.0636}],"compareEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0409},{"period":"6month","weight":0.0999},{"period":"1year","weight":0.2145},{"period":"ytd","weight":0.0403}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.073454},{"month":2,"riseRate":0.583333,"avgChangeRate":0.01602},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.021161},{"month":4,"riseRate":0.545455,"avgChangeRate":0.101832},{"month":5,"riseRate":0.636364,"avgChangeRate":0.1056},{"month":6,"riseRate":0.583333,"avgChangeRate":0.023074},{"month":7,"riseRate":0.583333,"avgChangeRate":0.109538},{"month":8,"riseRate":0.5,"avgChangeRate":0.045801},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.063785},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.046065},{"month":11,"riseRate":0.666667,"avgChangeRate":0.063018},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.062042}],"exchange":"NASDAQ","name":"Arcturus Therapeutics Ltd.","nameEN":"Arcturus Therapeutics Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Arcturus Therapeutics Ltd.(ARCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Arcturus Therapeutics Ltd.,ARCT,Arcturus Therapeutics Ltd.股票,Arcturus Therapeutics Ltd.股票老虎,Arcturus Therapeutics Ltd.股票老虎国际,Arcturus Therapeutics Ltd.行情,Arcturus Therapeutics Ltd.股票行情,Arcturus Therapeutics Ltd.股价,Arcturus Therapeutics Ltd.股市,Arcturus Therapeutics Ltd.股票价格,Arcturus Therapeutics Ltd.股票交易,Arcturus Therapeutics Ltd.股票购买,Arcturus Therapeutics Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Arcturus Therapeutics Ltd.(ARCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction